Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis

Täger, Tobias; Frankenstein, Lutz; Atar, Dan; Agewall, Stefan; Frey, Norbert; Grundtvig, Morten; Clark, Andrew L.; Cleland, John G. F.; Fröhlich, Hanna

doi:10.1007/s00392-021-01913-z

Table 1 Baseline characteristics of included trials

From: Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis

Record	Trial*	NCT number	Year	Active treatment	Comparator	Centers (n)	Patients (n)	Patients with HF (n, %)	Duration (weeks)	FU in patients with HF (py)
Bhatt [8]	SOLOIST-WHF	NCT03521934	2020	Sotagliflozin	Placebo	306	1222	1222 (100)	39	916.5
Butler [25], Fitchett [26, 27]	EMPA-REG-OUTCOME	NCT01131676	2016–2019	Empagliflozin	Placebo	590	7020	706 (10.1)	164	1835.6
Cannon [28], Cosentino [29]	VERTIS CV	NCT01986881	2020	Ertugliflozin	Placebo	567	8238	1958	42	1581.5
Carbone [30]	CANA-HF	NCT02920918	2019	Canagliflozin	Sitagliptin	1	36	36 (100)	12	8.3
de Boer [31]	Licogliflozin vs. empagliflozin vs. placebo	NCT03152552	2020	Licogliflozin	Empagliflozin, Placebo	55	124 ^b	124 (100)	12 ^b	28.6^†
Jensen [32]	EMPIRE-HF	NCT03198585	2020	Empagliflozin	Placebo	2	190	190 (100)	12	43.8
Kato [33]	DECLARE	NCT01730534	2019	Dapagliflozin	Placebo	882	17,160	1987 (11.6)	218.4	8345.4
Kosiborod [34] ^‡	1. Moderate KD (56) 2. Add-on to sulfonylurea [57] 3. Add-on to insulin [58] 4. High CV risk [59] 5. High CV risk [60]	1. NCT00663260 2. NCT00680745 3. NCT00673231 4. NCT01031680 5. NCT01042977	2014 2011 2012 2015 2014	Dapagliflozin	Placebo	111 84 126 141 173	252 592 808 922 964	19 (7.5) 13 (2.2) 18 (14.3) 118 (12.8) 152 (15.8)	52 48 48 52 § 52 §	19 12 16.6 922 964
Lee [35]	SUGAR-DM-HF	NCT0348509	2020	Empagliflozin	Placebo	15	105	105 (100)	36	72.7
McMurray [6, 36], Petrie [37]	DAPA-HF	NCT03036124	2019	Dapagliflozin	Placebo	417	4744	4744 (100)	78.8	7195.1
Nassif [38]	DEFINE-HF	NCT 02653482	2019	Dapagliflozin	Placebo	26	263	263 (100)	12	60.7
Packer [7], Anker [39]	EMPEROR-Reduced	NCT03057977	2020	Empagliflozin	Placebo	520	3730	3730 (100)	69	4973.3
Perkovic [40]	CREDENCE	NCT02065791	2019	Canagliflozin	Placebo	690	4397	652 (14.8)	136	1708.2
Radholm [41]	CANVAS Program	NCT01032629 and NCT01989754	2018	Canagliflozin	Placebo	667	10,142	1461 (14.4)	188.2	5282.1
Santos-Gallego [42]	EMPA-TROPISM	NCT 03485222	2020	Empagliflozin	Placebo	1	84	84	26	42
Singh [43]	REFORM	NCT02397421	2020	Dapagliflozin	Placebo	1	56	56	52	56
Boehringer Ingelheim [44] ^∥	EMPERIAL-Reduced	NCT03448419	2020	Empagliflozin	Placebo	109	312	312	12	72
Boehringer Ingelheim [45]^∥	EMPERIAL-Preserved	NCT03448406	2020	Empagliflozin	Placebo	108	315	315	12	72.7

HF heart failure, KD kidney disease, T2D type 2 diabetes mellitus
*Acronym/short title
^†Of the 124 patients randomized in the study, 80 were discontinued due to early study termination, with 44 patients completing the 12-weeks study
^‡This record presents a HF subgroup meta-analysis from five randomized controlled trials. Patients with HF included in any of the five trials have been identified retrospectively and data have been pooled for joint analyses
^§24-week trial plus 28-week (52-week) plus 52-week (104-week) extension period
^∥At the time of the literature search, results have not been published in a journal but were extracted from www.clinicaltrials.gov

Back to article page